Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)

This Phase 3, randomized, open-label, global trial is designed to assess the efficacy and safety of petosemtamab plus investigator's choice (IC) chemotherapy (fluorouracil + leucovorin (calcium folinate) + oxaliplatin \[mFOLFOX6\] or fluorouracil + leucovorin (calcium folinate) + irinotecan \[FOLFIRI\]) versus standard of care (SOC) (ie, cetuximab + IC chemotherapy \[mFOLFOX6 or FOLFIRI\]) as 1L therapy in participants with unresectable or metastatic left-sided colorectal cancer.